Phillip Pang - Feb 16, 2022 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
Chief Medical Officer
Signature
/s/ Howard Horn, Attorney-in-Fact
Stock symbol
VIR
Transactions as of
Feb 16, 2022
Transactions value $
-$246,130
Form type
4
Date filed
2/18/2022, 03:47 PM
Previous filing
Feb 4, 2022
Next filing
Feb 24, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Options Exercise $7.65K +5K +5.39% $1.53* 97.8K Feb 16, 2022 Direct
transaction VIR Common Stock Sale -$158K -5K -5.11% $31.54 92.8K Feb 16, 2022 Direct F1
transaction VIR Common Stock Sale -$96.1K -3.01K -3.24% $31.93 89.8K Feb 17, 2022 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Options Exercise $0 -5K -8.68% $0.00 52.6K Feb 16, 2022 Common Stock 5K $1.53 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on February 19, 2021.
F2 Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units.
F3 1/4 of the shares subject to the stock option vested and became exercisable on April 27, 2019, and the remaining shares vest in 36 equal monthly installments thereafter.